SAN DIEGO, CA – Mindera Corporation has announced that Martyn Gross was appointed Chief Business Officer and will head up efforts to commercialize the company’s groundbreaking Dermal Intelligence platform.
Mindera has a developed a novel platform to extract thousands of biomarkers (RNA, DNA, proteins) from an individual patient via a dermal biomarker patch. Captured RNA is then sent to a CLIA lab for Next-Generation Sequencing (NGS). Using Machine Learning, these biomarkers are correlated to clinical outcomes data from myriad psoriasis patients who receive specific biologic drugs, resulting in predictive analyses for personalized drug responses. Systemwide, predicting biologic responses through Mind.Px can result in both improved patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.
“Martyn brings a very diverse set of skills and experiences that will greatly benefit Mindera during this time of rapid growth and corporate development,” said George Mahaffey, CEO of Mindera. “His commercial acumen combined with relevant business development accomplishments at small companies is a critical addition to the team as we further our goal of generating clinically actionable data to support improved usage of personalized medicines in large dermatology markets.”
Mr. Gross brings a diverse background in medical devices, genomics, and digital therapeutics to Mindera. Previously, Mr. Gross was President of Stratify Genomics which commercialized a genetic test for lifetime predisposition to prostate cancer. There, he brought the company from a successful IP license to revenue and important commercial partnerships. Mr. Gross previously served as the COO of Dthera Sciences, a neurodegenerative disease therapy company that was given the first FDA Breakthrough Device status for a digital therapeutic. His prior role was as the founder of Clarify Medical, a novel connected home phototherapy device used by chronic skin disease patients. Mr. Gross serves as a strategic advisor to other personalized medical startups in the San Diego area. He holds an MBA from Rady School of Management, UC San Diego.
Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Find out more at www.minderadx.com.